Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab
- PMID: 32282956
- PMCID: PMC7262334
- DOI: 10.1002/ajh.25833
Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab
Conflict of interest statement
Bartolucci reports being a consultant for F. Hoffmann‐La Roche. No other potential conflict of interest relevant to this letter was reported.
Figures

Comment in
-
Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome.Am J Hematol. 2020 Aug;95(8):E192-E194. doi: 10.1002/ajh.25855. Epub 2020 May 16. Am J Hematol. 2020. PMID: 32358817 Free PMC article. No abstract available.
Similar articles
-
Red blood cell exchange to avoid intubating a COVID-19 positive patient with sickle cell disease?J Clin Apher. 2020 Aug;35(4):378-381. doi: 10.1002/jca.21809. Epub 2020 Jul 6. J Clin Apher. 2020. PMID: 32629539 Free PMC article.
-
Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.Med Clin (Barc). 2020 Nov 13;155(9):410-411. doi: 10.1016/j.medcli.2020.07.001. Epub 2020 Jul 9. Med Clin (Barc). 2020. PMID: 32718713 Free PMC article. No abstract available.
-
First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab.Blood Adv. 2020 Apr 14;4(7):1307-1310. doi: 10.1182/bloodadvances.2020001907. Blood Adv. 2020. PMID: 32243501 Free PMC article.
-
Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Ischemic Stroke.Stroke. 2020 Jul;51(7):e124-e127. doi: 10.1161/STROKEAHA.120.030153. Epub 2020 May 12. Stroke. 2020. PMID: 32396456 Review. No abstract available.
-
Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review.Rheumatol Int. 2020 Oct;40(10):1707-1716. doi: 10.1007/s00296-020-04635-z. Epub 2020 Jun 26. Rheumatol Int. 2020. PMID: 32591970 Free PMC article. Review.
Cited by
-
Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: An observational cohort study.EClinicalMedicine. 2020 Jul 1;24:100410. doi: 10.1016/j.eclinm.2020.100410. eCollection 2020 Jul. EClinicalMedicine. 2020. PMID: 32766535 Free PMC article.
-
Patients with sickle cell disease and suspected COVID-19 in a paediatric intensive care unit.Br J Haematol. 2020 Jul;190(1):e21-e24. doi: 10.1111/bjh.16802. Epub 2020 Jun 8. Br J Haematol. 2020. PMID: 32420608 Free PMC article. No abstract available.
-
Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.EBioMedicine. 2020 Jun;56:102822. doi: 10.1016/j.ebiom.2020.102822. Epub 2020 Jun 11. EBioMedicine. 2020. PMID: 32535547 Free PMC article. Review.
-
The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19.Front Immunol. 2020 Aug 11;11:1991. doi: 10.3389/fimmu.2020.01991. eCollection 2020. Front Immunol. 2020. PMID: 32903476 Free PMC article. Review.
-
Hyperhemolysis in a patient with sickle cell disease and recent SARS-CoV-2 infection, with complex auto- and alloantibody work-up, successfully treated with tocilizumab.Transfusion. 2022 Jul;62(7):1446-1451. doi: 10.1111/trf.16932. Epub 2022 May 30. Transfusion. 2022. PMID: 35588309 Free PMC article.
References
-
- Bulletin épidémiologique hebdomadaire [Internet]. http://beh.santepubliquefrance.fr/beh/2015/8/2015_8_2.html. Accessed April 3, 2020.
-
- Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med. 2000;342(25):1855‐1865. - PubMed
-
- Boissier F, Bagate F, Schmidt M, et al. Extracorporeal Life Support for Severe Acute Chest Syndrome in Adult Sickle Cell Disease: A Preliminary Report. Crit Care Med. 2019;47(3):e263‐e265. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical